AUTHORS
Gordon Cook, MD, PhD, DSc, Ethan Senior2, Kara-Louise Royle, PhD3, Charlotte Pawlyn, M.D., Ph.D.4, Dax Everritt5, Jenny Bird6, Stella Bowcock, MD, BA, FRCP, FRCPath, MA7, Bryony Dawkins8, Mark Drayson9, Sharon Gilson10, Catherine Olivier11, Lorna Barnard12, Leanne Kelly13, Matthew Jenner14, John Jones, MD15, Martin F Kaiser, MD,FRCP,FRCPath16, Bhuvan Kishore, MBBS, FRCPath, MRCP17, David Meads18, Neil Rabin, PhD, MBBS, FRCPath, MRCP19, Roger Owen, FRCPath20, Ruth de Tute, PhD, MSc, FRCPath21, Christopher Parrish, PhD, FRCPath, MA, MBBChir, MRCP22, Alan Chant23, David Cairns, PhD24, Graham Jackson, MBBS, DM, FRCP, FRCPath, MA25
AFFILIATIONS
1 University of Leeds, Leeds, West Yorkshire, United Kingdom
2 University of Leeds, Leeds, West Yorkshire, United Kingdom
3 University of Leeds, Leeds, West Yorkshire, United Kingdom
4 Institute of Cancer Research, London, United Kingdom
5 University of Leeds, Leeds, West Yorkshire, United Kingdom
6 University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
7 King's College Hospital, London, United Kingdom
8 University of Leeds, Leeds, United Kingdom
9 University of Birmingham, Birmingham, United Kingdom
10 University of Leeds, Leeds, West Yorkshire, United Kingdom
11 University of Leeds, Leeds, West Yorkshire, United Kingdom
12 University of Leeds, Leeds, West Yorkshire, United Kingdom
13 University of Leeds, Leeds, West Yorkshire, United Kingdom
14 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
15 Brighton & Sussex Medical School, Brighton, United Kingdom
16 Institute of Cancer Research, London, United Kingdom
17 University of Birmingham, Birmingham, United Kingdom
18 University of Leeds, Leeds, West Yorkshire, United Kingdom
19 University College London, London, United Kingdom
20 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
21 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
22 University of Leeds, Leeds, West Yorkshire, United Kingdom
23 University of Leeds, Leeds, West Yorkshire, United Kingdom
24 University of Leeds, Leeds, West Yorkshire, United Kingdom
25 Freemen of Newcastle-upon-Tyne, Newcastle upon Tyne, United Kingdom
ABSTRACT
Introduction:
Clinical and biological heterogeneity in newly diagnosed MM patients is well established and is particularly relevant in transplant non-eligible (TNE) patients. The International Myeloma Working Group frailty score (IMWG-FS) predicts survival, adverse events (AEs) and treatment tolerability, based on age (categorised), Katz Activity of Daily Living (ADL), Lawton’s Instrumental Activity of Daily Living (IADL) and Charlson Comorbidity Index (CCI). Groups are defined as FIT (IMWG-FS=0), UNFIT (IMWG-FS = 1) and FRAIL (IMWG-FS ≥ 2). Although baseline frailty influences trial key endpoints, it is unclear whether sustained changes in frailty are clinically impactful.
The UK-MRA Myeloma XIV FiTNEss trial (ISRCTN98606172) assessed IMWG-FS at baseline, after induction cycles 2, 4, 6 and 12, and after maintenance cycles 6 and 12. The frailty category as well as integer score were reported. We investigated how IMWG-FS changed during the trial and the impact of changes on outcomes.
Methods:
The difference in integer IMWG-FS between each patient baseline and their last frailty assessment performed on study was used to capture sustained changes of possible clinical significance. Patient age at trial entry was used to determine IMWG-FS throughout, so changes in IMWG-FS were not impacted by aging. Changes in CCI, ADL and IADL between frailty timepoints were descriptively summarised. Cox regression models of PFS and OS for sustained changes in IMWG-FS were fitted within each frailty group, adjusted for randomisation allocation, β2-microglobulin, haemoglobin, serum creatinine, corrected serum calcium and platelets.
Results:
Patients were most commonly FRAIL at baseline (FIT: 198/733 (27.0%), UNFIT: 241/733 (32.9%), FRAIL: 294/733 (40.1%)) and the most common IMWG-FS was 1 (0: 198/733 (27.0%); 1: 241/733 (32.9%); 2: 176/733 (24.0%); 3: 80/733 (10.9%); ≥4: 38/733 (5.2%)).
630/733 (85.9%) of patients had an IMWG-FS available for at least one timepoint beyond baseline. The median (IQR) time between first and last IMWG-FS assessments was 12.2 (IQR: 6.4, 22.1) months, showing that many changes were assessed long-term. Of these 630 patients, 190/630 (30.2%) had experienced a sustained change in IMWG-FS between baseline and their last frailty assessment performed on study. This was similar across treatment arms, but not across frailty category.
106/240 (44.2%) of initially FRAIL patients had a sustained change in IMWG-FS, of which 55/240 (22.9%) improved their IMWG-FS and 51/240 (21.3%) deteriorated. 54/215 (25.1%) of initially UNFIT patients had a sustained change in IMWG-FS (16/215 (7.4%) improved, 38/215 (17.7%) deteriorated). Initially, FIT patients could only have a deterioration in IMWG-FS, this was sustained in 30/175 (17.1%).
To investigate the underlying drivers of sustained change in IMWG-FS, intermediate time point changes were explored. During induction, changes in IMWG-FS were driven by the IADL with 7-17% of patients changing IADL score between any timepoints, compared to 3-10% for ADL and CCI. During maintenance, changes in IMWG-FS were more frequently driven by the CCI with 5-8% of patients changing CCI between any timepoints, compared to 2-5% for ADL and IADL.
Whilst sustained change in IMWG-FS did not significantly impact patient outcomes (p-value > 0.05), in FIT patients, sustained deterioration in IMWG-FS was associated with a trend toward shorter PFS (HR (95%CI):1.41 (0.84,2.38)) and OS (HR (95%CI):1.37 (0.56,3.36)). However, deterioration did not appear to adversely impact outcome in UNFIT and FRAIL patients. Sustained improvement in IMWG-FS was associated with a trend toward longer PFS and OS in UNFIT (HR (95%CI): PFS - 0.72 (0.33,1.57); OS - HR 0.76 (0.27,2.17)) and FRAIL (PFS - 0.68 (0.46,1); OS - HR 0.63 (0.39,1.03)) patients.
Conclusions:
In the FiTNEss trial, almost a third of patients experienced a sustained change in IMWG-FS between baseline and their last frailty assessment on study. These changes were more common in FRAIL patients and were largely driven by changes in functionality (IADL) during induction. This may reflect a greater potential for dynamism in the FRAIL group, though may be impacted by the integer score derivation of IMWG-FS in which the different frailty groups have different potential for change. Changes in IMWG-FS did not have a significant impact on PFS or OS, but trends emerged that should be further explored with longer follow-up.
DISCLOSURES
Gordon Cook, MD, PhD, DSc: Menarini Stemline - Honoraria; Pfizer - Honoraria; Johnson and Johnson - Honoraria; Sebia - Research Funding; BMS - Research Funding; Johnson and Johnson - Research Funding; Takeda - Research Funding; Menarini Stemline - Consultancy (Includes expert testimony); Takeda, Janssen-Cilag, Celgene, Karyopharm Therapeutics, Bristol Myers Squibb, Amgen, Oncopeptides, Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)